The interplay between hypoxia-associated miRNAs (hypoxamiRs) and the VEGF pathway represents a promising therapeutic avenue for ROP as preclinical models suggest that miRNA-based strategies may enhance the efficacy of anti-VEGF treatments in mitigating pathological angiogenesis and vascular instability. Here, VEGFA is linked to retinopathy of prematurity.